Bimekizumab - Revision history

Prab at 00:48, 27 April 2025

2025-04-27T00:48:19Z

@@ Line 1: / Line 1: @@
 {{Short description|Monoclonal antibody used in the treatment of psoriasis}}
 '''Bimekizumab''' is a [[monoclonal antibody]] used in the treatment of [[psoriasis]] and other inflammatory conditions. It is marketed under the trade name '''Bimzelx'''. Bimekizumab works by selectively inhibiting the activity of [[interleukin-17A]] (IL-17A) and [[interleukin-17F]] (IL-17F), which are cytokines involved in inflammatory processes.
@@ Line 42: / Line 22: @@
 * [[Interleukin-17]]
 * [[Autoimmune disease]]
+{{stub}}
 [[Category:Monoclonal antibodies]]
 [[Category:Immunosuppressants]]
 [[Category:Psoriasis treatments]]

Prab: CSV import

2025-03-22T19:18:13Z

CSV import

← Older revision		Revision as of 19:18, 22 March 2025
Line 1:		Line 1:
	{{~~Infobox drug~~		{{Short description\|Monoclonal antibody used in the treatment of psoriasis}}
	\| ~~type = mab~~		{{Drugbox
	~~\| image =~~		\| verifiedfields = changed
	\| ~~alt~~ =		\| verifiedrevid = 477002547
	\| ~~mab_type~~ = ~~mab~~		\| image = Bimekizumab.png
	\| ~~source = zu~~		\| width = 200px
	~~\| target = [[interleukin 17a\|IL17a]], [[interleukin 17f\|IL17f]]~~		\| type = mab
	~~\| pronounce~~ =		\| mab_type = mab
	~~\| tradename =~~		\| source = zu/o
	~~\| Drugs~~.~~com =~~		\| target = IL-17A, IL-17F
	\| ~~MedlinePlus~~ =		\| tradename = Bimzelx
	\| ~~pregnancy_AU~~ =		\| routes_of_administration = Subcutaneous
	\| ~~pregnancy_US~~ =		\| legal_status = Rx-only
	\| ~~pregnancy_category~~=		\| atc_prefix = L04
	\| ~~legal_AU~~ =		\| atc_suffix = AC21
	\| ~~legal_AU_comment~~ =		\| drugbank = DB15654
	\| ~~legal_BR =~~		\| chemspiderid = none
	~~\| legal_BR_comment =~~		\| kegg = D11468
	~~\| legal_CA =~~
	~~\| legal_UK =~~
	~~\| legal_US =~~
	~~\| legal_UN =~~
	~~\| legal_NZ~~ =
	\| legal_status =
	~~\| routes_of_administration =~~
	~~\| bioavailability~~ =
	~~\| protein_bound =~~
	~~\| metabolism =~~
	~~\| metabolites =~~
	~~\| onset =~~
	~~\| elimination_half~~-~~life =~~
	\| ~~duration_of_action~~=
	\| ~~excretion~~ =
	\| ~~CAS_number~~ = ~~1418205-77-2~~
	\| ~~ATC_prefix~~ = none
	\| ~~ATC_suffix =~~
	~~\| PubChem =~~
	~~\| DrugBank =~~
	~~\| KEGG = D11550~~
	~~\| C = \| H = \| N = \| O = \| S =~~
	~~\| molecular_weight =~~
	~~\| UNII~~ =
	\| synonyms =		\| synonyms =
	}}		}}

	'''Bimekizumab''' ([[~~International Nonproprietary Name\|INN~~]]~~<ref name=WHOList117>{{cite journal \| author =~~ [[~~World Health Organization~~]] ~~\| title = International Nonproprietary Names for Pharmaceutical Substances (INN)~~. ~~Proposed INN: List 110 \| journal = WHO Drug Information \| volume = 27 \| issue = 4 \| year = 2013 \| url = http://www~~.~~who.int/medicines/publications/druginformation/innlists/PL110.pdf \| format=PDF}}</ref>) is a monoclonal antibody that is being investigated for~~ [[~~ankylosing spondylitis~~]] and [[~~psoriasis~~]].		'''Bimekizumab''' is a [[monoclonal antibody]] used in the treatment of [[psoriasis]] and other inflammatory conditions. It is marketed under the trade name '''Bimzelx'''. Bimekizumab works by selectively inhibiting the activity of [[interleukin-17A]] (IL-17A) and [[interleukin-17F]] (IL-17F), which are cytokines involved in inflammatory processes.

	~~This drug~~ is ~~being developed by UCB~~. {{as of~~\|2018}},~~ bimekizumab is ~~undergoing~~ [[~~Phase III~~]] ~~trials~~.		==Mechanism of Action==
			Bimekizumab is a [[biologic therapy]] that targets and neutralizes IL-17A and IL-17F. These cytokines are part of the [[interleukin-17]] family, which plays a crucial role in the pathogenesis of [[autoimmune diseases]] such as psoriasis. By inhibiting these cytokines, bimekizumab reduces inflammation and the symptoms associated with psoriasis.

			==Clinical Use==
			Bimekizumab is primarily used for the treatment of moderate to severe [[plaque psoriasis]] in adults who are candidates for systemic therapy or [[phototherapy]]. It is administered via [[subcutaneous injection]].

			==Administration==
			The recommended dosage of bimekizumab is an initial dose followed by maintenance doses at regular intervals. The specific dosing schedule may vary based on the patient's response and the prescribing physician's recommendations.

			==Side Effects==
			Common side effects of bimekizumab include [[upper respiratory tract infections]], [[headache]], and [[injection site reactions]]. Serious side effects may include increased risk of infections, such as [[tuberculosis]], and hypersensitivity reactions.

			==Contraindications==
			Bimekizumab is contraindicated in patients with known hypersensitivity to the drug or any of its components. It should be used with caution in patients with a history of chronic infections or those who are immunocompromised.

			==Related Pages==
			* [[Psoriasis]]
			* [[Monoclonal antibody therapy]]
			* [[Interleukin-17]]
			* [[Autoimmune disease]]

	~~== References ==~~
	~~<references/>~~
	~~{{monoclonal-antibody-stub}}~~
	~~{{monoclonals for immune system}}~~
	[[Category:Monoclonal antibodies]]		[[Category:Monoclonal antibodies]]
	~~{{dictionary-stub1}}~~		[[Category:Immunosuppressants]]
			[[Category:Psoriasis treatments]]

Prab: CSV import

2024-02-20T19:37:56Z

CSV import

New page

{{Infobox drug
| type = mab
| image =
| alt =
| mab_type = mab
| source = zu
| target = [[interleukin 17a|IL17a]], [[interleukin 17f|IL17f]]
| pronounce =
| tradename =
| Drugs.com =
| MedlinePlus =
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category=
| legal_AU =
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA =
| legal_UK =
| legal_US =
| legal_UN =
| legal_NZ =
| legal_status =
| routes_of_administration =
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action=
| excretion =
| CAS_number = 1418205-77-2
| ATC_prefix = none
| ATC_suffix =
| PubChem =
| DrugBank =
| KEGG = D11550
| C = | H = | N = | O = | S =
| molecular_weight =
| UNII =
| synonyms =
}}

'''Bimekizumab''' ([[International Nonproprietary Name|INN]]<ref name=WHOList117>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110 | journal = WHO Drug Information | volume = 27 | issue = 4 | year = 2013 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL110.pdf | format=PDF}}</ref>) is a monoclonal antibody that is being investigated for [[ankylosing spondylitis]] and [[psoriasis]].

This drug is being developed by UCB. {{as of|2018}}, bimekizumab is undergoing [[Phase III]] trials.

== References ==
<references/>
{{monoclonal-antibody-stub}}
{{monoclonals for immune system}}
[[Category:Monoclonal antibodies]]
{{dictionary-stub1}}